Skip header and navigation

Refine By

40 records – page 1 of 4.

10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.

https://arctichealth.org/en/permalink/ahliterature141809
Source
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9
Publication Type
Article
Date
Aug-1-2011
Author
Juanita Crook
Jette Borg
Andrew Evans
Ants Toi
E P Saibishkumar
Sharon Fung
Clement Ma
Author Affiliation
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. jcrook@bccancer.bc.ca
Source
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9
Date
Aug-1-2011
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - blood - mortality - pathology - radiotherapy
Aged
Aged, 80 and over
Brachytherapy - adverse effects - methods
Disease-Free Survival
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Neoadjuvant Therapy - methods
Neoplasm Staging
Ontario
Penile Erection - physiology
Proportional Hazards Models
Prospective Studies
Prostate
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood - mortality - pathology - radiotherapy
Radiotherapy Dosage
Urination Disorders - drug therapy
Abstract
To report outcomes for 1,111 men treated with iodine-125 brachytherapy (BT) at a single institution.
A total of 1,111 men (median age, 63) were treated with iodine-125 prostate BT for low- or intermediate-risk prostate cancer between March 1999 and November 2008. Median prostate-specific antigen (PSA) level was 5.4 ng/ml (range, 0.9-26.1). T stage was T1c in 66% and T2 in 34% of patients. Gleason score was 6 in 90.1% and 7 or 8 in 9.9% of patients. Neoadjuvant hormonal therapy (2-6 months course) was used in 10.1% of patients and combined external radiotherapy (45 Gy) with BT (110 Gy) in 4.1% (n = 46) of patients. Univariate and multivariate Cox proportional hazards were used to determine predictors of failure.
Median follow-up was 42 months (range, 6-114), but for biochemical freedom from relapse, a minimum PSA test follow-up of 30 months was required (median 54; n = 776). There were 27 failures, yielding an actuarial 7-year disease-free survival rate of 95.2% (96 at risk beyond 84 months). All failures underwent repeat 12-core transrectal ultrasound -guided biopsies, confirming 8 local failures. On multivariate analysis, Gleason score was the only independent predictor of failure (p = 0.001; hazard ratio, 4.8 (1.9-12.4). Median International Prostate Symptom score from 12 to 108 months ranged between 3 and 9. Of the men reporting baseline potency, 82.8% retained satisfactory erectile function beyond 5 years.
Iodine-125 prostate BT is a highly effective treatment option for favorable- and intermediate-risk prostate cancer and is associated with maintenance of good urinary and erectile functions.
PubMed ID
20675072 View in PubMed
Less detail

Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey.

https://arctichealth.org/en/permalink/ahliterature158552
Source
Endocr Pract. 2008 Mar;14(2):175-84
Publication Type
Article
Date
Mar-2008
Author
Anna M Sawka
David P Goldstein
Lehana Thabane
James D Brierley
Richard W Tsang
Lorne Rotstein
Shamila Kamalanathan
Boyu Zhao
Amiram Gafni
Sharon Straus
Shereen Ezzat
Author Affiliation
Division of Endocrinology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
Source
Endocr Pract. 2008 Mar;14(2):175-84
Date
Mar-2008
Language
English
Publication Type
Article
Keywords
Canada
Carcinoma, Papillary - pathology - radiotherapy
Decision Making
Health Care Surveys
Humans
Iodine Radioisotopes - therapeutic use
Neoplasm Staging
Physician's Practice Patterns - standards - statistics & numerical data
Questionnaires
Thyroid Neoplasms - pathology - radiotherapy
United States
Abstract
To explore physician recommendations regarding radioiodine remnant ablation (RRA) as adjuvant treatment in early-stage well-differentiated thyroid carcinoma (WDTC), their rationale for administration of RRA, and their willingness to involve patients' opinions in decision making about the use of RRA.
We surveyed a representative sample of specialty physicians in Canada and the United States and asked survey participants whether they would recommend adjuvant RRA after thyroidectomy for a 1.6-cm papillary thyroid carcinoma (Likert scale of agreement responses from 1 to 7; strong agreement >or=6). Factor analysis was performed to explore the rationale for recommendations. We asked whether physicians accepted the role of patients' preferences in decision making about administration of RRA, and backward conditional logistic regression analysis was used to identify predictors of strong acceptance.
The effective response rate for the survey was 56.3% (486 of 864), with 62.8% (295 of 470 respondents) strongly recommending RRA. Strong RRA recommendations were founded in opinions that RRA (1) decreases WDTC-related mortality and recurrence and (2) facilitates WDTC follow-up at low risk of adverse effects. Approximately a third of the survey respondents (152 of 474) strongly agreed with incorporation of patients' preferences in decision making regarding the use of RRA. Physicians without firm convictions about the efficacy of RRA in decreasing disease-related outcomes and those practicing in the United States were most likely to indicate strong support for incorporating patients' preferences in decision making about RRA.
The recommendations of physicians regarding use of adjuvant RRA are founded in beliefs in intervention efficacy and follow-up practices. Physicians in medical practice in the United States and those without strong convictions about RRA efficacy are most likely to incorporate patients' views in individualizing decisions about RRA therapy.
PubMed ID
18308655 View in PubMed
Less detail
Source
Can Med Assoc J. 1985 Apr 15;132(8):925-31
Publication Type
Article
Date
Apr-15-1985
Author
W J Simpson
S E McKinney
Source
Can Med Assoc J. 1985 Apr 15;132(8):925-31
Date
Apr-15-1985
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - mortality - pathology - therapy
Adolescent
Adult
Aged
Canada
Carcinoma - mortality - pathology - therapy
Carcinoma, Papillary - mortality - pathology - therapy
Child
Combined Modality Therapy
Female
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Neoplasm Metastasis
Prognosis
Retrospective Studies
Thyroid Hormones - therapeutic use
Thyroid Neoplasms - mortality - pathology - therapy
Thyroidectomy
Abstract
We report the results of a multicentre retrospective chart review of 2214 patients with thyroid cancer registered at 13 radiotherapy centres between 1958 and 1978. The data analysed included sex, age at the time of diagnosis, pathological diagnosis, extent of disease before treatment, types of treatment and their complications, and the rates of recurrence and survival up to 24 years after diagnosis. Although papillary cancers were most common, anaplastic and miscellaneous tumours were more frequent than expected, which reflects the type of patients referred by endocrinologists and surgeons to radiotherapy centres. There were marked differences in patterns of referral to the centres. Some patients with papillary and follicular thyroid cancers died of these cancers up to 20 years after diagnosis. The clinical manifestations, treatment and outcome of the rarer types of thyroid malignant tumours were of particular interest. The influence of age at the time of diagnosis on survival rates for patients with papillary or follicular thyroid cancer was highly significant, indicating much more aggressive behaviour of these cancers in older patients, particularly those beyond the age of 60 years. A more detailed analysis of tumour subtypes should provide new information on their natural history and lead to better management.
Notes
Cites: Semin Nucl Med. 1971 Oct;1(4):481-5024107464
Cites: Eur J Cancer. 1979 Aug;15(8):1033-41510341
Cites: Medicine (Baltimore). 1977 May;56(3):171-96859443
Cites: Br J Cancer. 1977 Jan;35(1):1-39831755
PubMed ID
3978516 View in PubMed
Less detail

Cancer risks in thyroid cancer patients.

https://arctichealth.org/en/permalink/ahliterature24790
Source
Br J Cancer. 1991 Jul;64(1):159-63
Publication Type
Article
Date
Jul-1991
Author
P. Hall
L E Holm
G. Lundell
G. Bjelkengren
L G Larsson
S. Lindberg
J. Tennvall
H. Wicklund
J D Boice
Author Affiliation
Department of General Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Source
Br J Cancer. 1991 Jul;64(1):159-63
Date
Jul-1991
Language
English
Publication Type
Article
Keywords
Female
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Neoplasms, Radiation-Induced - etiology
Radiotherapy - adverse effects
Registries
Research Support, U.S. Gov't, P.H.S.
Risk factors
Sweden
Thyroid Neoplasms - radiotherapy - surgery
Thyroidectomy
Abstract
Cancer risks were studied in 834 thyroid cancer patients given 131I (4,551 MBq, average) and in 1,121 patients treated by other means in Sweden between 1950 and 1975. Record-linkage with the Swedish Cancer Register identified 99 new cancers more than 2 years after 131I therapy [standardised incidence ratio (SIR) = 1.43; 95% confidence interval (CI) 1.17-1.75] vs 122 (SIR = 1.19; 95% CI 0.88-1.42) in patients not receiving 131I. In females treated with 131I overall SIR was 1.45 (95% CI 1.14-1.83) and significantly elevated were noted for tumours of the salivary glands, genital organs, kidney and adrenal gland. No elevated risk of a subsequent breast cancer or leukaemia was noted. SIR did not change over time, arguing against a strong radiation effect of 131I. Organs that were estimated to have received more than 1.0 Gy had together a significantly increased risk of a subsequent cancer following 131I treatment (SIR = 2.59; n = 18). A significant trend was seen for increasing activities of 131I with highest risk for patients exposed to greater than or equal to 3,664 MBq (SIR = 1.80; 95% CI 1.20-2.58). No specific cancer or group of cancers could be convincingly linked to high-dose 131I exposures since SIR did not increase after 10 years of observation. However, upper confidence intervals could not exclude levels of risk that would be predicted based on data from the study of atomic bomb survivors. We conclude that the current practice of extrapolating the effects of high-dose exposures to lower-dose situations is unlikely to seriously underestimate radiation hazards for low LET radiation.
PubMed ID
1854616 View in PubMed
Less detail

Cardiovascular Morbidity and Mortality After Treatment of Hyperthyroidism with Either Radioactive Iodine or Thyroidectomy.

https://arctichealth.org/en/permalink/ahliterature299906
Source
Thyroid. 2018 09; 28(9):1111-1120
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
09-2018
Author
Essi Ryödi
Saara Metso
Heini Huhtala
Matti Välimäki
Anssi Auvinen
Pia Jaatinen
Author Affiliation
1 Heart Center Co., Tampere University Hospital , Tampere, Finland .
Source
Thyroid. 2018 09; 28(9):1111-1120
Date
09-2018
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adult
Aged
Cardiovascular Diseases - etiology - mortality
Female
Finland - epidemiology
Humans
Hyperthyroidism - complications - radiotherapy - surgery - therapy
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Registries
Retrospective Studies
Survival Rate
Thyroidectomy
Abstract
Hyperthyroid patients remain at an increased risk of cardiovascular diseases (CVDs) after restoring euthyroidism. The impact of the different treatment modalities of hyperthyroidism on future CVD risk remains unclear. The aims of this study were to assess cardiovascular morbidity and mortality in hyperthyroidism before and after treatment, and to compare the effects of two different treatment modalities: radioactive iodine (RAI) and thyroid surgery.
A comparative cohort study was conducted among 6148 hyperthyroid patients treated with either RAI or thyroidectomy and 18,432 age- and sex-matched controls. First, hospitalizations due to CVDs prior to the treatment were analyzed. Second, the hazard ratios (HR) for any new hospitalization and mortality due to CVDs after treatment were estimated among all the hyperthyroid patients compared to the age- and sex-matched controls and also in the RAI-treated patients compared to the thyroidectomy-treated patients. The results were adjusted for prevalent CVDs at the time of treatment.
Before treatment for hyperthyroidism, hospitalizations due to all CVDs were more common in the hyperthyroid patients compared to the controls (odds ratio?=?1.61 [confidence interval (CI) 1.49-1.73]). During the post-treatment follow-up, hospitalizations due to CVDs remained more frequent among the patients (HR?=?1.15 [CI 1.09-1.21]), but there was no difference in CVD mortality (HR?=?0.93 [CI 0.84-1.03]). Compared to the patients treated with thyroidectomy, the RAI-treated patients had a higher risk of hospitalization due to all CVDs (HR?=?1.17), atrial fibrillation (HR?=?1.28), as well as a higher CVD mortality rate (HR?=?2.56). Yet, treatment with RAI resulting in hypothyroidism was not associated with increased CVD morbidity compared to thyroidectomy.
Hyperthyroidism increases the risk of CVD-related hospitalization, and the risk is sustained for up to two decades after treatment with RAI or surgery. Hyperthyroid patients treated with RAI remain at a higher CVD risk compared to patients treated with thyroidectomy. Hypothyroidism during follow-up, however, predicts better cardiovascular outcomes.
Notes
ErratumIn: Thyroid. 2018 Dec;28(12):1731 PMID 30562155
PubMed ID
29882483 View in PubMed
Less detail

Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study.

https://arctichealth.org/en/permalink/ahliterature67684
Source
J Intern Med. 1996 Feb;239(2):165-71
Publication Type
Article
Date
Feb-1996
Author
G. Berg
A. Michanek
E. Holmberg
E. Nyström
Author Affiliation
Department of Oncology, Sahlgrenska University Hospital, University of Göteborg, Sweden.
Source
J Intern Med. 1996 Feb;239(2):165-71
Date
Feb-1996
Language
English
Publication Type
Article
Keywords
Adult
Age Distribution
Aged
Aged, 80 and over
Female
Follow-Up Studies
Goiter, Nodular - radiotherapy
Graves Disease - radiotherapy
Humans
Hyperthyroidism - complications - epidemiology - radiotherapy
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Quality of Life
Questionnaires
Research Support, Non-U.S. Gov't
Sex Distribution
Smoking - adverse effects
Sweden - epidemiology
Treatment Outcome
Abstract
OBJECTIVES. To study the clinical outcome of treatment of hyperthyroid patients with radioiodine. DESIGN. Records of patients treated for hyperthyroidism with radioiodine from 1989 to 1992 were examined in 1994, and a questionnaire was sent to patients
PubMed ID
8568485 View in PubMed
Less detail

A comparison between ¹²5Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma.

https://arctichealth.org/en/permalink/ahliterature117095
Source
Br J Ophthalmol. 2013 Mar;97(3):327-32
Publication Type
Article
Date
Mar-2013
Author
Hatem Krema
Mostafa Heydarian
Akbar Beiki-Ardakani
Daniel Weisbrod
Wei Xu
E Rand Simpson
Arjun Sahgal
Author Affiliation
Department of Ocular Oncology, University of Toronto, Toronto, Ontario, Canada. htmkrm19@yahoo.com
Source
Br J Ophthalmol. 2013 Mar;97(3):327-32
Date
Mar-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Brachytherapy - methods
Choroid Neoplasms - diagnosis - therapy
Female
Follow-Up Studies
Humans
Incidence
Iodine Radioisotopes - therapeutic use
Male
Melanoma - diagnosis - therapy
Middle Aged
Neoplasm Recurrence, Local - epidemiology
Ontario - epidemiology
Radiosurgery - methods
Retrospective Studies
Survival Rate - trends
Treatment Outcome
Abstract
To compare the treatment efficacy and radiation complications between (125)Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma.
Consecutive juxtapapillary melanoma patients treated with radiotherapy were included. Patients were divided into two cohorts: patients treated with (125)Iodine brachytherapy and patients with stereotactic radiotherapy. Comparison included the rates postradiotherapy local recurrence, secondary enucleation, metastasis and radiotherapy complications. Kaplan-Meier estimates were used to determine the actuarial rates, and logrank test to compare between the estimates.
We included 94 patients with juxtapapillary melanoma treated with radiotherapy. The brachytherapy cohort included 30 patients and stereotactic radiotherapy was 64. The median follow-up was 46 months in both cohorts. No statistically significant differences existed between the two cohorts on comparing pretreatment clinical data and tumour characteristics. On comparing treatment efficacy, the actuarial rates at 50 months for tumour recurrence were 11% and 7% (p=0.61), secondary enucleation was 11% and 21% (p=0.30) and for metastasis were 4% and 16% (p=0.11), respectively. On comparing treatment complications, the actuarial rates at 50 months for cataracts were 62% and 75% (p=0.1), for neovascular glaucoma 8% and 47% (p=0.002), for radiation retinopathy 59% and 89% (p=0.0001), and for radiation papillopathy 39% and 74% (p=0.003), respectively.
Both (125)Iodine brachytherapy and stereotactic radiotherapy demonstrate comparable efficacy in the management of juxtapapillary choroidal melanoma. However, stereotactic radiotherapy shows statistically significant higher radiation-induced ocular morbidities at 4 years postradiotherapy.
PubMed ID
23335213 View in PubMed
Less detail

Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident.

https://arctichealth.org/en/permalink/ahliterature21839
Source
Arch Surg. 1998 Jan;133(1):89-93
Publication Type
Article
Date
Jan-1998
Author
P. Miccoli
A. Antonelli
C. Spinelli
M. Ferdeghini
P. Fallahi
L. Baschieri
Author Affiliation
Endocrine Surgery Unit, University of Pisa, Italy.
Source
Arch Surg. 1998 Jan;133(1):89-93
Date
Jan-1998
Language
English
Publication Type
Article
Keywords
Accidents, Radiation
Adolescent
Byelarus
Carcinoma, Papillary - etiology - pathology - surgery
Child
Female
Humans
Hypoparathyroidism - etiology
Iodine Radioisotopes - therapeutic use
Lung Neoplasms - secondary
Lymphatic Metastasis
Male
Neoplasm Recurrence, Local
Postoperative Complications
Power Plants
Thyroid Neoplasms - etiology - pathology - radiotherapy - surgery
Thyroidectomy
Treatment Outcome
Ukraine
Vocal Cord Paralysis - etiology
Abstract
OBJECTIVE: To evaluate the usefulness of submitting children with thyroid cancer secondary to nuclear accidents to a completion total thyroidectomy. DESIGN: A case series consisting of patients living and operated on in Belarus whose parents had asked for a clinical evaluation in a western European center. SETTING: A tertiary care referral center. PATIENTS: The conditions of 47 children from Gomel, Belarus, with differentiated thyroid carcinoma following the nuclear accident at Chernobyl, Ukraine, were evaluated at the University of Pisa, Pisa, Italy. In approximately half of the cases, the treatment in Belarus consisted of a hemithyroidectomy. After a complete evaluation, the decision was made to reoperate on 19 of them by performing a completion total thyroidectomy. The preoperative evaluation revealed that 5 (26%) of the 19 patients who had undergone a hemithyroidectomy had unilateral recurrent nerve palsy and that 2 (10.5%) had hypoparathyroidism. INTERVENTIONS: Neck ultrasonography was used for the preoperative localization of thyroid residuals, thyroid nodules, suspicious lymph nodes, and a guided fine-needle aspiration biopsy specimen. The circulating thyroglobulin measurement was obtained before reoperation. An iodine 131 whole-body scan (WBS) was performed and circulating thyroglobulin levels were obtained after completion of the thyroidectomy during withdrawal of levothyroxine sodium therapy. MAIN OUTCOME MEASURE: The number of patients with a recurrence of thyroid cancer and lung or lymph node metastases after the completion total thyroidectomy. RESULTS: The results of the histologic examination were positive for papillary thyroid cancer in 6 (28.6%) of 21 patients, 3 with residual cancer in the remaining thyroid lobe and 3 with metastatic lymph node disease. A posttherapy WBS demonstrated lung metastases in 5 (28%) of 18 patients and lymph node metastases in 6 (33%) of 18 patients; the results of a posttherapy WBS were negative for metastases in 7 (39%) of 18 patients. Hypoparathyroidism developed in 4 (21%) of 19 patients who underwent a completion total thyroidectomy; unilateral laryngeal nerve palsy developed in 1 (5.2%) of these 19 patients. Among 22 children who previously underwent total thyroidectomy in Belarus, a diagnostic WBS showed lung metastases in 10 (45%) of the children and lymph node metastases alone in 3 (14%) of the children; the results of a diagnostic WBS were negative for metastases in 9 (41%) of the children. Statistical analysis showed a nonsignificant (P>.05) difference in the prevalence of lung and lymph node metastases in patients who previously underwent total thyroidectomy compared with patients who underwent completion total thyroidectomy. CONCLUSION: Completion total thyroidectomy allowed for the diagnosis and treatment of recurrent thyroid cancer and lung or lymph node metastases in 61% (11/18) of the patients in whom residual differentiated thyroid carcinoma was not previously recognized.
PubMed ID
9438766 View in PubMed
Less detail

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

https://arctichealth.org/en/permalink/ahliterature193967
Source
Arch Ophthalmol. 2001 Jul;119(7):969-82
Publication Type
Article
Date
Jul-2001
Author
M. Diener-West
J D Earle
S L Fine
B S Hawkins
C S Moy
S M Reynolds
A P Schachat
B R Straatsma
Source
Arch Ophthalmol. 2001 Jul;119(7):969-82
Date
Jul-2001
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Brachytherapy
Canada - epidemiology
Choroid Neoplasms - diagnosis - mortality - radiotherapy
Eligibility Determination
Eye Enucleation
Female
Humans
Iodine Radioisotopes - therapeutic use
Male
Melanoma - diagnosis - mortality - radiotherapy
Middle Aged
Odds Ratio
Patient Selection
Postoperative Complications
Survival Rate
United States - epidemiology
Abstract
To report initial mortality findings from the Collaborative Ocular Melanoma Study (COMS) randomized clinical trial of iodine 125 brachytherapy vs enucleation for treatment of choroidal melanoma.
Patients were evaluated for eligibility at 43 participating clinical centers in the United States and Canada. Eligible consenting patients were assigned randomly at the time of enrollment to enucleation or 125I brachytherapy. Patients were examined at specified intervals after enrollment for data collection purposes. Findings presented herein are based on data received by September 30, 2000. Data for each patient were analyzed with the treatment group to which the patient was assigned randomly at the time of enrollment.
During the 11(1/2)-year accrual period, 1317 patients enrolled; 660 were assigned randomly to enucleation and 657 to 125I brachytherapy. Only 2 patients in the enucleation arm were found to have been misdiagnosed when histopathology was reviewed centrally. All but 17 patients (1.3%) received the assigned treatment. Adherence to the brachytherapy protocol was excellent, with 91% of patients treated per protocol. Based on time since enrollment, 1072 patients (81%) had been followed for mortality for 5 years and 416 (32%) for 10 years. A total of 364 patients had died: 188 (28%) of 660 patients in the enucleation arm and 176 (27%) of 657 patients in the brachytherapy arm. The unadjusted estimated 5-year survival rates were 81% and 82%, respectively; there was no clinically or statistically significant difference in survival rates overall (P =.48, log-rank test). The adjusted estimated risk ratio for 125I brachytherapy vs enucleation was 0.99 (95% confidence interval [CI], 0.80-1.22). Five-year rates of death with histopathologically confirmed melanoma metastasis were 11% and 9% following enucleation and brachytherapy, respectively; after adjustment, the estimated risk ratio was 0.91 (95% CI, 0.66-1.24).
Mortality rates following 125I brachytherapy did not differ from mortality rates following enucleation for up to 12 years after treatment of patients with choroidal melanoma who enrolled in this COMS trial. The power of the study was sufficient to indicate that neither treatment is likely to increase or decrease mortality rates by as much as 25% relative to the other.
Notes
Comment In: Arch Ophthalmol. 2001 Jul;119(7):1067-811448330
PubMed ID
11448319 View in PubMed
Less detail

[Danish endocrinologists' examination and treatment of non-toxic multinodular goiter. A questionnaire study]

https://arctichealth.org/en/permalink/ahliterature19928
Source
Ugeskr Laeger. 2001 Feb 26;163(9):1265-9
Publication Type
Article
Date
Feb-26-2001
Author
S J Bonnema
F N Bennedbaek
L. Hegedüs
Author Affiliation
Odense Universitetshospital, medicinsk endokrinologisk afdeling M. steen.bonnema@dadlnet.dk
Source
Ugeskr Laeger. 2001 Feb 26;163(9):1265-9
Date
Feb-26-2001
Language
Danish
Publication Type
Article
Keywords
Adult
Denmark
English Abstract
Female
Goiter, Nodular - diagnosis - therapy
Health Knowledge, Attitudes, Practice
Humans
Iodine Radioisotopes - therapeutic use
Male
Physician's Practice Patterns
Questionnaires
Research Support, Non-U.S. Gov't
Thyroid Function Tests
Thyroid Gland - pathology - radionuclide imaging - ultrasonography
Thyroid Hormones - blood
Thyroidectomy
Abstract
AIM: To assess the attitudes towards the management of the non-toxic multinodular goitre by means of a questionnaire concerning on case history, which was circulated to all Danish endocrinologists ("A 42-year-old woman with an irregular, non-tender, bilaterally enlarged thyroid of 50-80 g and no clinical suspicion of malignancy"). DESIGN: Eleven variations of the (basic) case report were proposed in order to evaluate the impact on the management of each alteration. In the index case, serum TSH was the routine choice of 100%, serum T4/free T4-index and T3/free T3-index were measured by 83% and 79%, serum TPOab and serum calcitonin by 49% and 4%, respectively. RESULTS: The median number of blood tests was three (range 1-7). Thyroid scintigraphy was used by 96% and ultrasound by 94%, both methods were employed by 90% with scintigraphy most often having the first priority. Fine-needle aspiration biopsy was not routinely used, unless a scintigraphically dominant "cold" area was present; 70% used ultrasound guidance. Radioiodine was the preferred treatment of 51%, surgery 7%, L-T4 4%, and no treatment 38%. DISCUSSION: In the case of young patients or factors predisposing to thyroid cancer, treatment preferences changed to surgery. The prevailing use of radioiodine in Denmark contrasts with the situation in most other European countries, but Danish endocrinologists also disagree about the optimum management of multinodular non-toxic goitre.
PubMed ID
11258250 View in PubMed
Less detail

40 records – page 1 of 4.